Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN), a biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
Investors and interested parties can access a live webcast of the fireside chat through a provided link and on the company's website at www.designtx.com in the investors section. The webcast will remain archived for at least 30 days after the presentation, allowing for later viewing.
This participation in a major healthcare conference highlights Design Therapeutics' commitment to engaging with the investment community and sharing updates on their progress in developing innovative treatments for genetic diseases.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DSGN gained 15.69%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) participating in the 2024 Cantor Global Healthcare Conference?
How can I watch Design Therapeutics' (DSGN) fireside chat at the Cantor Global Healthcare Conference?
What is the focus of Design Therapeutics (DSGN) as a biotechnology company?
How long will the webcast of Design Therapeutics' (DSGN) fireside chat be available?
